Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kodiak Sciences Inc

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

On the latest edition of CNBC's “Mad Money Lightning Round,” Jim Cramer called Kodiak Sciences Inc. (NASDAQ:KOD) is a “pure spec” stock.

Benzinga · Aug 27, 2025

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga · Aug 8, 2022

United Airlines And 3 Other Stocks Insiders Are Buying

Although US stocks closed slightly higher on Monday, there were a few notable insider trades.

Benzinga · Jun 7, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Kodiak Sciences Shares Are Plunging Today

Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-related macular degeneration.

Benzinga · Feb 23, 2022

Read Why Barclays Analyst Is 'Negatively Biased' On Kodiak Sciences

Barclays has lowered the firm's price target on Kodiak Sciences Inc (NASDAQ: KOD

Benzinga · Feb 7, 2022

People

Jim Cramer

549 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

TRACON Pharmaceuticals

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.